David Dausch is the senior director of RTI’s Technology Advancement & Commercialization (TAC) business unit. He leads TAC’s multi-disciplinary team of over 60 staff, including scientists and engineers who perform research in advanced materials, biomedical technologies, decarbonization sciences, environmental exposure and protection, and sustainable energy solutions. Using our engineering expertise and laboratory systems capabilities, TAC develops technologies and solutions to improve human health, mitigate climate change, provide clean energy, and support military service members.
He manages RTI’s SIGMA+ Health wearable sensor research platform, an end-to-end data collection and analytics solution for improving military Service members health, readiness, and performance. He serves as Principal Investigator for the Human-Based Sensor System for Presymptomatic Biological Exposure Detection research project for the SIGMA+ program sponsored by the Defense Advanced Research Projects Agency (DARPA).
Dr. Dausch has more than 25 years of experience in R&D and technology commercialization. Previously, he served as the Microelectromechanical Systems (MEMS) Technologies Team Leader at RTI, where he managed R&D programs for government and commercial clients. He was the lead inventor of a novel intracardiac medical imaging technology and subsequently served as Chief Technology Officer for startup company Envisage Medical to commercialize the technology. He also supported technology transfer and innovation capacity-building programs in the Middle East and helped launch a startup R&D and technology acceleration company in the region. His work has been published in more than 90 scientific and technical publications and presentations and in 16 U.S. patents.
